CASE REPORT

A case of palisaded neutrophilic granulomatous dermatitis with subsequent development of chronic myelomonocytic leukemia

Aikaterini Kyriakou¹ | Aikaterini Patsatsi¹ | Vassilios Papadopoulos² | Anna Kioumi² | Ioannis Efstratiou³ | Elizabeth Lazaridou¹

Correspondence

Aikaterini Kyriakou, 2nd Department of Dermatology and Venereology, General Hospital "Papageorgiou", Thessaloniki, Greece.

Email: docmouli@gmail.com

Key Clinical Message

Palisaded neutrophilic granulomatous dermatitis is a cutaneous marker of a systemic disease. Clinicians' goal should be directed toward determining an underlying condition. Even if the initial investigation is inconclusive, it may be necessary that some tests are repeated, since a serious underlying disease could be revealed in the course of time.

KEYWORDS

connective tissue, lymphoproliferative, rheumatoid arthritis, sarcoidosis

1 | INTRODUCTION

Palisaded neutrophilic granulomatous dermatitis (PNGD) is an infrequent histopathological diagnosis usually associated with an underlying systemic disease, 1 such as connective tissue disease, rheumatoid arthritis, sarcoidosis, lymphoproliferative disorder, vasculitis, infection, and inflammatory bowel disease.^{2,3} Infrequently, PNGD may be either idiopathic, with no identified cause, or drug-induced. 4-6 PNGD may precede or occur concomitantly with the underlying disease.^{1,7} Its clinical presentation varies; however, PNGD usually presents as erythematous to violaceous papules or plaques with central umbilication or necrosis, mostly distributed symmetrically on the extensor surfaces of the upper extremities, head, or neck.8 A case of a patient with skin lesions that were histopathologically compatible with PNGD is presented, with subsequent development of chronic myelomonocytic leukemia (CMML).

2 | CASE HISTORY/ EXAMINATION

A 59-year-old male was admitted to our Department with a 3-month history of fatigue, fevers, and unintentional weight loss over this period. He also reported a 2-week history of violaceous, mildly tender, indurated plaques located on the extensor surfaces of the upper extremities, and head (Figure 1).

3 | DIFFERENTIAL DIAGNOSIS, INVESTIGATIONS, AND TREATMENT

The patient had no significant medical history and received no medications regularly. Over the last 3 months, plenty of tests had been performed to investigate the fever of unknown origin. A full blood count had revealed normocytic anemia with leukocytosis and monocytosis, as well

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Clin Case Rep. 2019;7:695–698. wileyonlinelibrary.com/journal/ccr3 | 695

¹2nd Department of Dermatology and Venereology, General Hospital "Papageorgiou", Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

²Hematology Department, General Hospital "Papageorgiou", Thessaloniki, Greece

³Pathology Department, General Hospital "Papageorgiou", Thessaloniki, Greece



FIGURE 1 Violaceous, indurated plaques located on the head

as immature granulocytes in the peripheral blood smear (WBC: 14.4×10^9 /L, neutrophils/lymphocytes/monocytes: 57/23/18%, absolute counts: 8.18, 3.37, 2.59×10^9 /L respectively, hemoglobin: 102 G/L, platelets: 234×10^9 /L). He had also had elevated inflammatory markers (CRP: 12 mg/dL). Liver function tests had been normal, except for mildly elevated lactate dehydrogenase (LDH: 267 IU/L). The patient had been tested negative for a number of autoimmune and infective diseases. At initial presentation, bone marrow biopsy had revealed a small percentage (15%) of nonclonal plasma cells, suggestive of an extra-medullary




FIGURE 2 Initial bone marrow smear showing sparse plasma cells (arrows) and reactive changes—May-Grunwald-Giemsa (MGG) stain x 100




FIGURE 3 Formation of granulomas—H&E X 10

disease (Figure 2). During the referral to our Department, a skin biopsy was performed and revealed lymphocytes and eosinophils, palisading granulomas, and neutrophilic debris (Figures 3 and 4), which was compatible with the diagnosis of PNGD. Subsequently, the patient was followed closely with repeated blood smears.

4 | OUTCOME AND FOLLOW-UP

During the follow-up, the anemia gradually deteriorated and transfusions of red blood cells were required, while thrombocytopenia was developed. After 5 months from the skin biopsy, the complete blood counts were as follows: WBC: 12.7×10^9 /L, neutrophils: 4.45×10^9 /L, lymphocytes 1×10^9 /L, monocytes: 4.7×10^9 /L, Hb: 75 G/L, PLT: 60×10^9 /L (Figure 5A). Subsequently, another bone marrow biopsy was conducted, which revealed greatly increased cellularity, presence of 14% myeloblasts and 6% monocytes, and morphological dysplasia of erythroid and





FIGURE 4 Neutrophilic infiltration and nuclear debris—H&E X 40






FIGURE 5 A, Peripheral blood on follow-up suggestive of CMML. B, Bone marrow smear on follow-up suggestive of CMML. Arrowheads: abnormal monocytes, black arrowheads: blasts, white arrowhead: dysplastic neutrophil, red arrowheads: dysplastic erythroblasts. (MGG x100). B, upper left image (x10) depicts increased cellularity

megakaryocytic lineage (Figure 5B). After exclusion of other myeloproliferative neoplasms (JAK2 - V617F, BCR/ABL negative), and according to WHO-2018 criteria, the diagnosis of CMML-2 was reached. The cytogenetic analysis of bone marrow showed complex karyotype and peripheral blood flow cytometry further supported the diagnosis. Unfortunately, the patient passed away a few days after the diagnosis of his hematologic condition, due to cardiac arrest. No treatment for his condition had ever been initiated.

5 | DISCUSSION

Pathogenesis of PNGD remains poorly understood. Direct immunofluorescence studies have suggested immune complex deposition. ⁹ Lately, it has been suggested that the granulomas may represent a nonspecific immunological response possibly related to the underlying disease. ¹⁰

Palisaded neutrophilic granulomatous dermatitis proceeds through different histologic stages⁹; thus, clincopathologic correlation is compulsory.^{8,11}A single biopsy may not initially reveal the combination of findings indicative of PNGD.¹¹ Early lesions show diffuse neutrophils with or without leukocytoclastic vasculitis and degenerated collagen; fully developed lesions present palisaded granulomas surrounding leukocytoclastic debris, and altered collagen.^{1,12} In our case, the patient showed fully developed lesions characterized histologically by the presence of neutrophilic infiltration and nuclear debris, as well as granulomas.

Palisaded neutrophilic granulomatous dermatitis is benign disease and its management is based on the control of the underlying disease. However, plenty therapeutic options have been reported such as systemic corticosteroids, colchicine, cyclosporine, cyclophosphamide, hydroxychloroquine, and dapsone. In our case, no action was taken, since the patient passed away a few days after the diagnosis of his hematologic condition, due to cardiac arrest.

The association between PNGD and hematological malignancies has been reported constantly, ^{8,14,15} Therefore, it is strongly recommended to differentiate it from leukemic infiltrates. ¹⁴ Infiltration of the skin by leukemic cells is quite rare in CMML and may predict a rapid aggressive course and a shift to a blast transformation of the disease. ^{16,17} Cutaneous lesions may present as erythematous rashes, plaques, nodules, or pigmented nodules without any typical clinical features and with heterogeneous histopathologic features. ^{16,17}

The concurrence of PNGD and CMML has been reported recently by Federmann et al, who presented three patients with disseminated lesions histopathologically consistent with PNGD and persistent monocytosis. ¹⁴ An important aspect of our case is that the cutaneous lesions were one of the first clinical complaints in our patient contributing significantly to the diagnosis of his hematological disorder. ¹⁴

The identification of PNGD is of great importance, since it is a cutaneous marker of systemic disease. ¹⁰ Clinicians' goal should be directed toward determining an underlying condition. ^{4,8} Even if the initial investigation is inconclusive, it may be necessary that some tests are repeated, since a serious underlying disease could be revealed in the course of time.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTION

AK, VP: collected clinical data and wrote the manuscript. AP, AK, VP, IE, EL: contributed to patient's evaluation and follow-up. AP, EL: reviewed the manuscript. All authors read and approved the final version of the manuscript.

ORCID

Aikaterini Kyriakou https://orcid.org/0000-0002-7594-8512

REFERENCES

- Bremner R, Simpson E, White CR, et al. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum. 2004;34(3):610-616.
- Stiff KM, Cohen PR. Palisaded granulomatous dermatitis associated with ulcerative colitis: a comprehensive literature review. *Cureus*. 2017;9(1):e958.
- Gordon EA, Schmidt AN, Boyd AS. Palisaded neutrophilic and granulomatous dermatitis: a presenting sign of sarcoidosis? *J Am Acad Dermatol*. 2011;65(3):664-665.
- 4. Fett N, Kovarik C, Bennett D. Palisaded neutrophilic granulomatous dermatitis without a definable underlying disorder treated with dapsone. *J Am Acad Dermatol*. 2011;65(3):e92-e93.
- Gordon K, Miteva M, Torchia D, et al. Allopurinol-induced palisaded neutrophilic and granulomatous dermatitis. *Cutan Ocul Toxicol*. 2012;31(4):338-340.
- Singh M, Comfere N. Images in clinical medicine. Palisaded neutrophilic and granulomatous dermatitis. N Engl J Med. 2012;366(22):e33.
- 7. Hantash BM, Chiang D, Kohler S, et al. Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis. *J Am Acad Dermatol*. 2008;58(4):661-664.
- Alavi A, Sajic D, Cerci FB, et al. Neutrophilic dermatoses: an update. Am J Clin Dermatol. 2014;15(5):413-423.

- Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. *Arch Dermatol*. 1994;130(10):1278-1283.
- Deen J, Banney L, Perry-Keene J. Palisading neutrophilic and granulomatous dermatitis as a presentation of Hodgkin lymphoma: a case and review. *J Cutan Pathol*. 2018;45(2):167-170.
- 11. Kalen JE, Shokeen D, Ramos-Caro F, et al. Palisaded neutrophilic granulomatous dermatitis: Spectrum of histologic findings in a single patient. *JAAD Case Rep.* 2017;3(5):425-428.
- 12. Al-Daraji WI, Coulson IH, Howat AJ. Palisaded neutrophilic and granulomatous dermatitis. *Clin Exp Dermatol*. 2005;30(5):578-579.
- 13. Jung KH, Jeong S, Kwon SR, et al. Palisaded neutrophilic granulomatous dermatitis in a patient with systemic sclerosis-rheumatoid arthritis overlap syndrome. *Ann Dermatol.* 2017;29(6):804-806.
- 14. Federmann B, Bonzheim I, Yazdi AS, et al. Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases. *Hum Pathol*. 2017;64:198-206.
- 15. Swing DC, Sheehan DJ, Sangueza OP, et al. Interstitial granulomatous dermatitis secondary to acute promyelocytic leukemia. *Am J Dermatopathol.* 2008;30(2):197-199.
- Mathew RA, Bennett JM, Liu JJ, et al. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. *Leuk Res*. 2012;36(1):72-80.
- Loghavi S, Curry JL, Garcia-Manero G, et al. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. *J Cutan Pathol*. 2017;44(12):1075-1079.

How to cite this article: Kyriakou A, Patsatsi A, Papadopoulos V, Kioumi A, Efstratiou I, Lazaridou E. A case of palisaded neutrophilic granulomatous dermatitis with subsequent development of chronic myelomonocytic leukemia. *Clin Case Rep.* 2019;7:695–698. https://doi.org/10.1002/ccr3.2072